Novartis AG - 28 Year Stock Split History | NVS

Stock split history for Novartis AG since 1996. Prices shown are actual historical values and are not adjusted for either splits or dividends. Please see the "Historical Prices" tab for adjusted price values.
Novartis AG Annual Stock Splits
Novartis AG Quarterly Stock Splits
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $216.930B $45.440B
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $814.944B 117.78
Novo Nordisk (NVO) Denmark $590.290B 45.36
Johnson & Johnson (JNJ) United States $372.289B 14.76
Merck (MRK) United States $318.551B 57.96
AbbVie (ABBV) United States $304.294B 15.72
AstraZeneca (AZN) United Kingdom $244.043B 21.22
Pfizer (PFE) United States $169.828B 21.11
Sanofi (SNY) $128.207B 12.08
Innoviva (INVA) United States $1.073B 7.54